COQ6

COQ6 encodes a mitochondrial FAD-dependent flavoprotein monooxygenase that performs ring-modification steps in coenzyme Q (ubiquinone) biosynthesis, and its loss abolishes CoQ synthesis with downstream bioenergetic failure (PMID:12721307, PMID:21944752, PMID:31379988). The protein is imported into mitochondria in a membrane-potential-dependent manner and acts as a peripheral membrane protein on the matrix side of the inner mitochondrial membrane, where coq6 loss causes accumulation of the early intermediate 3-hexaprenyl-4-hydroxybenzoic acid (PMID:12721307). Its principal catalytic role is the C5-hydroxylation of the CoQ benzene-ring precursor, receiving electrons in vivo from the ferredoxin/ferredoxin reductase pair Yah1/Arh1, and it additionally catalyzes an oxygen-dependent C4-deamination when para-aminobenzoic acid serves as precursor — two activities separable by point mutations and modulated by Coq9 (PMID:21944752, PMID:26260787). Substrate handling depends on a hydrophobic access channel for the bulky prenylated substrate, and enzymatic function requires the FAD cofactor (PMID:26808124). In human cells, COQ6 knockout abolishes CoQ, producing ATP deficiency and ROS overproduction with accumulation of 3-decaprenyl-1,4-benzoquinone, indicating that decarboxylation and C1-hydroxylation precede the COQ6-catalyzed C5-hydroxylation in mammals (PMID:31379988). Loss-of-function COQ6 mutations cause a CoQ-deficiency disease presenting as steroid-resistant nephrotic syndrome/FSGS with sensorineural deafness, with COQ6 acting in podocytes and inner-ear stria vascularis; podocyte-specific deletion in mice produces FSGS and massive proteinuria (PMID:21540551, PMID:30737270). Across yeast, cultured human cells, and mouse models, hydroxylated precursor analogs (vanillic acid, 3,4-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid) bypass COQ6 deficiency and restore CoQ biosynthesis, respiration, and organ function (PMID:21944752, PMID:24140869, PMID:31379988, PMID:30737270).

1. 2003 High

   Established that COQ6 is a flavin-dependent monooxygenase required for CoQ biosynthesis and pinned its position downstream of the 3-hexaprenyl-4-hydroxybenzoic acid intermediate, defining where in the pathway it acts.

   Evidence Functional complementation cloning, mitochondrial import and submitochondrial fractionation, and metabolite accumulation analysis in yeast

   PMID:12721307

   Open questions at the time

   • Did not assign the specific chemical reaction catalyzed
   • Electron donors not identified
2. 2011 High

   Resolved COQ6's specific reaction as the C5-hydroxylation step and identified its in vivo electron donors, also showing that hydroxylated precursor analogs bypass the deficiency.

   Evidence Yeast genetic complementation, metabolic labeling, bypass assays with substrate analogs, and electron-donor mutant analysis

   PMID:21944752

   Open questions at the time

   • Direct in vitro reconstitution of the hydroxylase reaction not reported
   • Did not address additional catalytic activities
3. 2011 High

   Connected human COQ6 loss-of-function to disease by showing patient mutations fail to complement yeast and cause podocyte/zebrafish apoptosis rescuable by CoQ10, establishing a CoQ-deficiency nephropathy with cochlear involvement.

   Evidence Yeast complementation of patient alleles, siRNA and zebrafish morpholino knockdown, tissue immunolocalization, and CoQ10 rescue

   PMID:21540551

   Open questions at the time

   • Reported Golgi/cell-process localization in podocytes alongside mitochondrial role not mechanistically reconciled
   • Genotype-phenotype correlation across alleles incomplete
4. 2013 High

   Characterized human COQ6 isoforms and patient alleles, showing most disease mutations are hypomorphic and that an FAD-domain-truncated isoform is inactive, clarifying residual-activity biology and rescue potential.

   Evidence Yeast complementation with human isoforms and patient mutations, protein stability assessment, and analog bypass rescue

   PMID:24140869

   Open questions at the time

   • Proposed regulatory/inhibitory role of inactive isoform b not directly demonstrated
   • Endogenous human isoform abundances not quantified
5. 2015 High

   Demonstrated a second catalytic activity—oxygen-dependent C4-deamination on the pABA-derived precursor—separable from C5-hydroxylation by mutation and influenced by Coq9, expanding COQ6 to a bifunctional enzyme.

   Evidence 18O2 isotope labeling, site-directed mutagenesis dissecting the two activities, and Δcoq9 genetic epistasis in yeast

   PMID:26260787

   Open questions at the time

   • Molecular basis of Coq9 influence on COQ6 not defined
   • Relevance of C4-deamination in mammals using pABA not established
6. 2016 Medium

   Provided a structural rationale for substrate handling by modeling a hydrophobic access channel and validating channel-blocking mutations in vivo, linking enzyme architecture to function.

   Evidence Biochemical FAD cofactor characterization, homology modeling, molecular dynamics with substrate docking, and in vivo assays of predicted mutations

   PMID:26808124

   Open questions at the time

   • No experimental structure; model is homology-based
   • Channel and catalytic mechanism not confirmed by crystallography or cryo-EM
7. 2017 Medium

   Identified post-translational regulation of CoQ output via a Coq7 phosphorylation cycle controlled by the phosphatase Ptc7, linking COQ6/CoQ levels to mitochondrial function and lifespan.

   Evidence Yeast Ser/Thr mutagenesis of Coq7, CoQ6 quantification, respiratory and ROS assays, and PTC7 deletion/overexpression

   PMID:28357388

   Open questions at the time

   • Regulation acts on Coq7 rather than direct COQ6 modification
   • Single-lab yeast study; mammalian conservation untested
8. 2019 High

   Defined the mammalian reaction order and bioenergetic consequences of COQ6 loss using human knockouts, showing intermediate accumulation, ATP deficiency, ROS rise, and analog rescue.

   Evidence CRISPR/Cas9 knockout in human cells with CoQ, ATP, ROS, and metabolite measurements plus vanillic acid rescue

   PMID:31379988

   Open questions at the time

   • Enzymes for the upstream decarboxylation/C1-hydroxylation not assigned here
   • In vitro enzymatic kinetics not measured
9. 2019 High

   Established organ-level causality and a non-canonical podocyte phenotype by showing podocyte-specific Coq6 deletion causes FSGS/proteinuria and a migration defect, both rescued by 2,4-dihydroxybenzoic acid.

   Evidence Podocyte-specific conditional knockout mice with albuminuria readout, human podocyte knockdown migration assay, and 2,4-diHB pharmacological rescue

   PMID:30737270

   Open questions at the time

   • Mechanism linking CoQ deficiency to impaired podocyte migration not resolved
   • Hearing phenotype not addressed in this model

• How COQ6's two catalytic activities and its substrate channel are coordinated within the CoQ biosynthetic complex, and the molecular basis of Coq9-dependent regulation, remain unresolved.
• No experimental atomic structure of COQ6
• Direct enzymatic reconstitution and kinetics absent
• Mechanism of Coq9 modulation undefined